Clinical Trial Update: A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Bomedemstat versus best available therapy in essential thrombocythemia patients with inadequate response or intolerance to hyd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• Bomedemstat (bomedemstat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Essential Thrombocythemia | Phase 3 | Status: RECRUITING